Feature | April 25, 2014

New Heart Assist Pump Allows Minimally Invasive Approach at Vanderbilt Heart and Vascular Institute

heartware lvads vanderbilt heart heartmate

The new HeartWare left ventricular assist device (LVAD) is implanted through a minimally invasive approach and sits inside the chest, connecting directly to the heart.

April 25, 2014 — Vanderbilt Heart and Vascular Institute (VHVI) was the first facility in Tennessee to implant the miniaturized HeartWare HVAD pump through a minimally invasive approach known as a thoracotomy, a small incision on the side of the chest.

The HVAD pump is a miniaturized, full output device designed to be implanted in the pericardial space. It sits inside the chest and connects directly to the heart. No abdominal dissection is required in the implant procedure. The mechanically operated heart pump is meant to bridge heart failure patients to transplantation.

Last year, Simon Maltais, M.D., assistant professor of cardiac surgery and director of the heart transplant and ventricular support program at VHVI, traveled to the University Heart Center in Leipzig, Germany, to observe Martin Strueber, M.D., and Jan Schmitto, M.D., of Hanover, Germany, as they implanted the HeartWare device. They are now considered pioneers of the minimally invasive LVAD (left ventricular assist device) approach.

Over the last year, VHVI became the largest minimally invasive LVAD center in the United States. To date, Maltais has implanted 50 HeartWare devices, 40 percent of them minimally invasively, which requires a small 4-6 cm incision. This approach avoids opening the chest through a sternotomy, thus decreasing operating room (OR) time, risk of perioperative bleeding and infection.

“We try to minimize splitting the sternum, which can be very traumatic. This facilitates the reoperation for the eventual heart transplant. It’s a very big advantage,” Maltais said.

Combined with another LVAD device known as HeartMate II, which VHVI started using in 2008, Vanderbilt performed 82 LVAD procedures in 2013, placing it in the top five medical centers in the country for the number of implants. All told, LVAD survival rates are at 90 percent at Vanderbilt, Maltais said.

The HeartMate II is a high-speed axial flow rotary blood pump. It drains blood continuously from the left ventricle to the aorta by the action of the internal rotor, leading to improved long-term performance.

An article that appeared recently in the New England Journal of Medicine outlined an increased rate of pump thrombosis (blood clots) with the HeartMate II. Vanderbilt, which has a collaborative relationship with the Mayo Clinic and the University of Michigan to study LVAD outcomes, had not observed this trend. Maltais and John Stulak, M.D., of the Mayo Clinic, studied the outcomes from 516 HeartMate II pump implants performed at the three institutions and submitted their results to the NEJM. Their letter, written in response to the original article, appeared in the April 10 issue of the journal.

While the group’s findings confirmed a similar peak in pump thrombosis in 2012, it unanimously observed a decrease in 2013, according to the NEJM letter.

“These observations were found consistent at each individual center before combining data. While the field is indebted to the report by Starling et al, we have observed a different trajectory in confirmed pump thrombosis incidence more recently,” the authors wrote. “While we believe this important information should be available to readers, it reaffirms the need to standardize patient management in this challenging population.”

“This work will be widely cited in the upcoming years and proves our ability to be in the top of advanced heart failure centers in the country. Our advanced heart failure research program is very productive and is part of making the field progress,” Maltais said.

For more information: www.mc.vanderbilt.edu

Related Content

Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD) | May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD) | April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD) | April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD) | March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD) | March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
Overlay Init